What it sells
Multi-targeted therapeutics to treat complex diseases
Business model breakdown
Workflow: what inputs become what output?
Machine-learning generative chemistry tunes out anti-targets and tunes in secondary targets to design multi-targeted precision-pharmacology molecules.
Economics: what it saves and how it charges
UnverifiedDrug-discovery company: value comes from developing medicines and partnering with pharma (deal terms not disclosed).
Distribution: how it reaches customers
Partnership outreach via a contact form on the Partnerships page.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.